Metsera (NASDAQ: MTSR)
$27.68
(9.1%)
$2.30
Price as of June 18, 2025, 3:58 p.m. ET
Metsera Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Metsera Company Info
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.